Immunological aspects of intestinal mucus and mucins
Breaking News, Collaborations & Alliances Novo Nordisk, Ascendis Ink $285M GLP-1 Pact To leverage Ascendis TransCon technology platform for once-monthly GLP-1 receptor agonist candidate
The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Yulan Egan Aug 21, 2024 6 min read Across the past two years, GLP-1 agonistsa class of drugs that treat type 2 diabetes (T2D) and obesityhave not only become a major source of industry discourse, but a household name
It is a great anti-oxidant, so it really removes the toxins
In 2021, the FDA approved it as a treatment for weight loss
Novo previously partnered with Him & Hers for selling compounded versions of semaglutide, the active ingredient in Novos Wegovy and Ozempic drugs